Facebook Twitter RSS Feed
 - cancer

Navidea, based in Dublin, Ohio, announced yesterday that the radiopharmaceutical company has received orphan drug designation for the small molecular radiotracer technetium-99m tilmanocept (Lymphoseek) specifically for sentinel lymph node mapping in cancer cases of the head and neck.

 - LDCT Lung Cancer Screening

Quantitative PET metrics including metabolic tumor volume using F-18 FDG can project heath outcomes after chemoradiotherapy for patients with non-small cell lung cancer (NSCLC), according to a study presented Wednesday during the 2013 Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) held Sept. 14-17 at the Moscone Center in San Francisco.

 - patient

External beam radiotherapy (EBRT) was compared with a combination therapy of EBRT and brachytherapy to see which provided long-term sexual health for patients with prostate cancer. Results indicated that both treatment plans led to a high level of sexual function due to isolated radiation, according to a study presented during the 2014 annual meeting of the American Society for Radiation Oncology (ASTRO) being held Sept. 14-17 at the Moscone Center in San Francisco.

 - Proton Therapy Gantry

As the American Society for Radiation Oncology (ASTRO) concludes today at the Moscone Center in San Francisco, Molecular Imaging caught up with two experts in proton therapy technology and policy—David C. Beyer, MD, president-elect of ASTRO, and Sameer R. Keole, MD, vice chair of ASTRO’s government relations council and a radiation oncologist at the Mayo Clinic in Phoenix—to talk about how this cutting-edge technology is changing.

 - Barry A. Siegel, MD

As the 2014 Annual Meeting for the Society of Nuclear Medicine and Molecular Imaging (SNMMI) came to a close this year in St. Louis, Molecular Imaging Insight sat down with Barry A. Siegel, MD, professor of radiology and medicine and chief of the nuclear medicine division at local Washington University School of Medicine.